Affordable Access

deepdyve-link
Publisher Website

Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma

Authors
  • Shen, Jiayu1
  • Sun, Xiwen2
  • Zhou, Jianwei1
  • 1 Department of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou , (China)
  • 2 Department of Obstetrics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou , (China)
Type
Published Article
Journal
Frontiers in Oncology
Publisher
Frontiers Media SA
Publication Date
Aug 28, 2020
Volume
10
Identifiers
DOI: 10.3389/fonc.2020.01263
PMID: 32983962
PMCID: PMC7485315
Source
PubMed Central
Keywords
License
Unknown

Abstract

Ovarian malignancies remain the leading cause of death in female gynecological tumors. More than 70% of patients are diagnosed with advanced stage with extensive metastatic lesions in abdominal cavity due to lack of symptoms in early stage and sensitive diagnostic approaches. Mesothelin (MSLN), a glycosylphosphatidylinositol-anchored membrane glycoprotein, participates in cell adhesion, tumor progression, metastasis, and drug resistance. Despite this, the mechanism is still poorly understood. The differential expression pattern of MSLN in normal and cancer tissues makes it a promising target for diagnosis and therapeutic applications. Several clinical trials are underway to evaluate the safety and efficacy of MSLN-targeted drugs, including CAR T cells, immunotoxin, antibody-drug conjugates, and vaccine. This review is aimed to briefly discuss the characteristics of MSLN and the latest progress in MSLN targeting therapies.

Report this publication

Statistics

Seen <100 times